Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Payables (2018 - 2025)

Summit Therapeutics' Payables history spans 8 years, with the latest figure at $22.2 million for Q3 2025.

  • For Q3 2025, Payables fell 19.84% year-over-year to $22.2 million; the TTM value through Sep 2025 reached $22.2 million, down 19.84%, while the annual FY2024 figure was $4.6 million, 73.83% up from the prior year.
  • Payables reached $22.2 million in Q3 2025 per SMMT's latest filing, down from $23.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $103.3 million in Q2 2024 to a low of $710000.0 in Q1 2023.
  • Average Payables over 5 years is $21.5 million, with a median of $6.4 million recorded in 2024.
  • Peak YoY movement for Payables: plummeted 89.8% in 2023, then soared 10370.11% in 2024.
  • A 5-year view of Payables shows it stood at $4.4 million in 2021, then surged by 360.11% to $20.1 million in 2022, then crashed by 86.75% to $2.7 million in 2023, then skyrocketed by 73.83% to $4.6 million in 2024, then surged by 379.83% to $22.2 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Payables are $22.2 million (Q3 2025), $23.0 million (Q2 2025), and $5.0 million (Q1 2025).